ICAM1 and small cell lung carcinoma: In addition, a trend toward a higher risk of death and high ICAM-1 levels (p = 0.06) was revealed by correlative studies of a phase II trial assessing the efficacy and safety of a bevacizumab and cisplatin, etoposide combination in 63 patients with extensive stage small-cell lung cancer [33].